Furosemide - Cutanea Life Sciences

Drug Profile

Furosemide - Cutanea Life Sciences

Alternative Names: CLS 006

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cutanea Life Sciences
  • Class Antihypertensives; Heart failure therapies; Small molecules; Sulfanilamides
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Warts

Most Recent Events

  • 01 Sep 2017 Phase-III clinical trials in Warts (In children) in USA (Topical) (NCT03259620)
  • 01 Sep 2017 Cutanea Life Sciences initiates enrolment in a phase III trial in Warts (In adolescents, In adults, In the elderly) in USA (Topical) (NCT03259620)
  • 30 Aug 2017 Cutanea Life Sciences plans a phase III trial for Warts (In children, In adolescents, In adults, In elderly) (NCT03259620)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top